Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jun 4;135(23):2106-2109.
doi: 10.1182/blood.2019004162.

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S Neelapu  1 , Caron A Jacobson  2 , Olalekan O Oluwole  3 , Javier Munoz  4 , Abhinav Deol  5 , David B Miklos  6 , Nancy L Bartlett  7   8 , Ira Braunschweig  9 , Yizhou Jiang  10 , Jenny J Kim  10 , Lianqing Zheng  10 , John M Rossi  10 , Frederick L Locke  11
Affiliations
Clinical Trial

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S Neelapu et al. Blood. .

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.S.N. has received personal fees from Kite, Merck, Novartis, Celgene, Pfizer, Allogene, Cell Medica, Incyte, Precision Biosciences, Legend Biotech, and Unum Therapeutics and research support from Kite, Bristol-Myers Squibb, Merck, Poseida, Cellectis, Celgene, Karus Therapeutics, Unum Therapeutics, Allogene, and Acerta. C.A.J. has received personal fees from Kite, Novartis, Precision Bioscience, Bayer, Pfizer, and Humanigen. J.M. has served in a consultancy or advisory role for Genentech, Alexion, Bayer, Bristol-Myers Squibb, Juno/Celgene, Kite, Kyowa, Merck, Pfizer, Pharmacyclics/Janssen, and Seattle Genetics; has served on speakers’ bureaus for AstraZeneca, Bayer, Fosunkite, Genentech, Kite, Kyowa, Pharmacyclics/Janssen, and Seattle Genetics; and has received research funding from Celgene, Genentech, Incyte, Janssen, Kite, Pharmacyclics, Portola, and Seattle Genetics. A.D. has served on advisory boards for Kite, Agios, and Novartis and has received research funding from Bristol-Myers Squibb. D.B.M has received grants and research funding from and served on a scientific advisory board for Kite. N.L.B has received research funding from Affimed, Bristol-Myers Squibb, Celgene, Forty Seven, Genentech, Gilead, Immune Design, Kite, Merck, Millennium, and Pharmacyclics and serves on advisory boards for Acerta and ADC Therapeutics. I.B. has received speaker fees from Kite. Y.J., J.J.K., L.Z., and J.M.R. are employees of Kite and have equity ownership in Gilead Sciences Inc. F.L.L has been a scientific advisor to Kite, Novartis, and GammaDelta Therapeutics and is a consultant for Cellular Biomedicine Group Inc. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
CAR T-cell expansion, DOR, and PFS by age group in ZUMA-1 phase 2 patients. (A) Peak levels (left) and AUC (days 0-28; right) of anti-CD19 CAR T cells per µL blood in patients ≥65 and <65 years of age. Phase 2 patients (n = 101) are shown. CAR T-cell levels were not available for 3 patients. (B) DOR among responders ≥65 and <65 years of age. (C) PFS in patients ≥65 and <65 years of age. AUC, area under the curve; CI, confidence interval; NE, not estimable.
See this image and copyright information in PMC

Comment in

References

    1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276. - PMC - PubMed
    1. Shipp MA, Harrington DP, Anderson JR, Armitage JO; International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987-994. - PubMed
    1. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas, version 5.2019. Plymouth Meeting, PA: National Comprehensive Cancer Network, Inc; 2019. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 4 November 2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Referenced with permission. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]. Blood. 2017;130(16):1800-1808. - PMC - PubMed
    1. Sun L, Li S, El-Jawahri A, et al. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis. Oncologist. 2018;23(5):624-630. - PMC - PubMed